BioMarin Pharmaceutical (BMRN) Financial Analysis & Valuation | Quarter Chart
BioMarin Pharmaceutical (BMRN)
BMRNPrice: $57.67
Fair Value: 🔒
🔒score
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage... more
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-... more
Description
Shares
| Market Cap | $11.15B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Alexander Hardy |
| IPO Date | 1999-07-26 | CAGR | 0.34% |
| Employees | 3,040 | Website | www.biomarin.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.32% | Total Yield | 0.32% |
BMRN chart loading...
Fundamentals
Technicals
| Enterprise Value | $10.97B | P/E Ratio | 27.73 |
| Forward P/E | 8.92 | PEG Ratio | -0.96 |
| P/S Ratio | 3.74 | P/B Ratio | 1.94 |
| P/CF Ratio | 13.78 | P/FCF Ratio | 15.78 |
| EPS | $2.08 | EPS Growth 1Y | -48.33% |
| EPS Growth 3Y | 272.75% | EPS Growth 5Y | -65.76% |
| Revenue Growth 1Y | 9.9% | Gross Margin | 0.76% |
| Operating Margin | 0.14% | Profit Margin | 0.08% |
| ROE | 0.04% | ROA | 0.03% |
| ROCE | 0.06% | Current Ratio | 5.81 |
| Quick Ratio | 4.2 | Cash Ratio | 2.8 |
| Debt/Equity | 0.23 | Interest Coverage | 19.1 |
| Altman Z Score | 3.97 | Piotroski Score | 5 |